The Company’s investigational small moleculeglucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss ...

Novo Nordisk today presented new data from the OASIS 4 phase 3 trial that explored a variety of patients and hypotheses, ...

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Semaglutide, the diabetes drug at the center of a global boom in weight-loss treatments, has entered the Moroccan market through a partnership between Danish pharmaceutical company Novo Nordisk and ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

Novo Nordisk said Wednesday it has agreed to the U.S. Inflation Reduction Act’s (IRA) negotiated maximum fair prices for ...

Over 24% of Indian adults across all states are now considered overweight or obese with more than 12.5 million children under ...

The guidance change marks the latest adjustment Novo has made to its 2025 outlook as the company battles a changing market.

Novo Nordisk A/S delivered mixed Q3 '25 results, with modest revenue growth but 27% drop in net profit due to financing costs ...